Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.35 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL492649 | 0.94 | ALDH1A1 (0.38) | L3MBTL1RAB9AALDH1A1PKMNPC1 | |
| SCHEMBL492726 | 0.90 | ALDH1A1 (0.46) | L3MBTL1RAB9AALDH1A1PKMNPC1 | |
| SCHEMBL492556 | 0.89 | L3MBTL1 (0.42) | L3MBTL1RAB9AALDH1A1PKMNPC1 | |
| SCHEMBL492764 | 0.88 | ALDH1A1 (0.46) | RAB9AALDH1A1PKMNPC1USP2 | |
| SCHEMBL493099 | 0.87 | NPC1 (0.43) | L3MBTL1RAB9AALDH1A1NPC1NCOA1 | |
| SCHEMBL493106 | 0.87 | NPC1 (0.36) | RAB9AALDH1A1NPC1NCOA1NCOA3 | |
| SCHEMBL492855 | 0.87 | NPC1 (0.39) | L3MBTL1RAB9AALDH1A1NPC1NCOA1 | |
| SCHEMBL493094 | 0.84 | ALDH1A1 (0.47) | L3MBTL1RAB9AALDH1A1PKMNPC1 | |
| SCHEMBL492697 | 0.83 | ALDH1A1 (0.47) | RAB9AALDH1A1PKMNPC1USP2 | |
| SCHEMBL493197 | 0.83 | RAB9A (0.39) | RAB9AALDH1A1NPC1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | claimed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | claimed |
| US-8106055-B2 | Substituted amide compounds | GRUENENTHAL GMBH (DE) | 2012-01-31 | — | — | US | disclosed |
| US-20080306084-A1 | Substituted Amide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306084-A1 | Substituted Amide Compounds | OPRK1, NAA50, ACMSD | L3MBTL1 4753/4885RAB9A 2004/4885ALDH1A1 1349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.